Targeting HER2 antibody drug conjugateENHERTU for breast cancer, gets quick review by the European Medicines Agency

Daiichi/AstraZeneca, Inc.,an antibody drug conjugate dating her2 ENHERTU (FAM-traszumab deruxtecan-nxki) for the treatment ofbreast cancerand obtained an accelerated review by the European DrugAdministrationBureau (EMA)The drug was approved by the U.SFood and Drug Administration (
FDA) in December to treat patients with HER2-positive metastatic breast cancer who have previously received two or more treatments based on the anti-HER2 regimenFDA approval and THE EMA's accelerated review are based on data from the DESTINY-Breast01 trial, which evaluated ENHERTU in patients previously treated with Herceptin, Perjeta, or KadcylaThe results showed that ENHERTU reached an objective mitigation rate of 60%, including more than 4% of total mitigation, and the median mitigation period was 14.8 monthsAZ reached a $6.9 billion cooperation agreement with Daiichi in March last year to commercialize ENHERTUanalysts predict edited that AZ/Daiichi's drug could replace Kadcyla as a multibillion-dollar drug with sales of up to $12 billion